Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib Maintenance Therapy After alloSCT in AML and MDS With IDH1 Mutation
NCT06717958Phase 2Recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Jun 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Technische Universität Dresden. Primary endpoint: Event-Free Survival at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06717958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717958.